BIAFW
IndustrialsBioAffinity Technologies Inc - Warrants(23/06/2027)
Live · NASDAQ · May 9, Close
What's Moving BIAFW Today?
No stock-specific AI insight has been generated for BIAFW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
BIAFW News
20 articles- bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® LungYahoo Finance·May 8, 2026
- bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and TreatmentYahoo Finance·Apr 28, 2026
- bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?Yahoo Finance·Apr 16, 2026
- New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary BiopsyYahoo Finance·Apr 14, 2026
- bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16Yahoo Finance·Apr 7, 2026
- bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026Yahoo Finance·Apr 1, 2026
- bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary PracticeYahoo Finance·Mar 25, 2026
- BC-Most Active StocksYahoo Finance·Mar 23, 2026
- New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive ProceduresYahoo Finance·Mar 17, 2026
- bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer TestYahoo Finance·Feb 25, 2026
- New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung CancerYahoo Finance·Feb 19, 2026
- bioAffinity Technologies Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 14, 2025
- bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test VolumeYahoo Finance·Nov 5, 2025
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung DiseasesYahoo Finance·Oct 28, 2025
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025Yahoo Finance·Oct 20, 2025
- bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung CancerYahoo Finance·Oct 16, 2025
- bioAffinity Technologies Regains Compliance with Nasdaq Listing RequirementsYahoo Finance·Oct 15, 2025
- WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 9, 2025
- bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 9, 2025
- WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq RulesYahoo Finance·Oct 8, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About BioAffinity Technologies Inc - Warrants(23/06/2027)
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.